Inflammatory mechanisms influence tumorigenesis and metastatic progression even in cancers whose aetiology does not involve pre-existing inflammation or infection, such as breast and prostate cancers 1 . For instance, prostate cancer metastasis is associated with the infiltration of lymphocytes into advanced tumours and the upregulation of two tumour-necrosis-factor family members: receptor activator of nuclear factor-kB (RANK) ligand (RANKL) and lymphotoxin 2 . But the source of RANKL and its role in metastasis have not been established. RANKL and its receptor RANK control the proliferation of mammary lobuloalveolar cells during pregnancy 3 through inhibitor of nuclear factor-kB (IkB) kinase-a (IKK-a) 4 , a protein kinase that is needed for the self-renewal of mammary cancer progenitors 5 and for prostate cancer metastasis 2 . We therefore examined whether RANKL, RANK and IKK-a are also involved in mammary/breast cancer metastasis. Indeed, RANK signalling in mammary carcinoma cells that overexpress the proto-oncogene Erbb2 (also known as Neu) 6 , which is frequently amplified in metastatic human breast cancers 7, 8 , was important for pulmonary metastasis. Metastatic spread of Erbb2-transformed carcinoma cells also required CD4
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1 CD25 1 T cells, whose major pro-metastatic function was RANKL production. Most RANKL-producing T cells expressed forkhead box P3 (FOXP3), a transcription factor produced by regulatory T cells, and were located next to smooth muscle actin (SMA) 1 stromal cells in mouse and human breast cancers. The dependence of pulmonary metastasis on T cells was replaceable by exogenous RANKL, which also stimulated pulmonary metastasis of RANK 1 human breast cancer cells. These results are consistent with the adverse impact of tumour-infiltrating CD4 1 or FOXP3 1 T cells on human breast cancer prognosis 9, 10 and suggest that the targeting of RANKL-RANK can be used in conjunction with the therapeutic elimination of primary breast tumours to prevent recurrent metastatic disease.
RANK signalling controls osteoclastogenesis and bone resorption and has been targeted to prevent bone metastasis in breast and prostate cancers [11] [12] [13] . A humanized anti-RANKL antibody seems to be a more effective inhibitor of bone metastasis than other osteoclast-targeting drugs 12, 13 . To examine whether RANK signalling controls additional aspects of breast cancer metastasis, we used mice on the FVB/N background in which Erbb2 was expressed under the control of the mouse mammary tumour virus promoter (MMTV-Erbb2-transgenic mice) 6 . In these mice, mammary carcinomas are induced by a gene that is overexpressed in 30% of human breast cancers 7 . Because Rank-null mice are osteopetrotic and have retarded growth 11 , we used MMTVErbb2-transgenic Rank 1/2 heterozygotes on the FVB/N background (MMTV-Erbb2/Rank 1/2 ), which were indistinguishable from MMTVErbb2/Rank 1/1 mice (on the same background) in appearance, weight and general health. Although reduced Rank gene dosage did not affect primary tumour development, tumoral RANK expression was reduced, and MMTV-Erbb2/Rank 1/2 mice gave rise to 50% fewer lung metastases than did MMTV-Erbb2/Rank 1/1 mice (Fig. 1a) . The role of RANK signalling was further examined using an orthotopic tumour model in which primary mammary carcinoma cells from an MMTVErbb2 tumour (PCaM cells) were injected into the number 2 mammary gland of FVB/N mice. Injection of recombinant RANKL, after inoculation with tumour cells, significantly increased the incidence and multiplicity of pulmonary metastases (Fig. 1b) .
We also generated an immortalized Erbb2-induced mammary carcinoma cell line, MT2, which doubled every 24 h, showed epithelial morphology, and formed colonies in soft agar and mammospheres when grown in suspension without serum ( Supplementary Fig. 1a-c) . MT2 cells expressed as much RANK as did PCaM cells. However, RANK expression was very low in non-transformed mammary epithelial cells from tumour-free virgins, and neither PCaM nor MT2 cells expressed RANKL ( Supplementary Fig. 1d, e) . After transplantation to the number 2 mammary gland, MT2 cells underwent pulmonary metastasis that was further enhanced by RANKL injection (Fig. 1c) . To ascertain that the results were not affected by a putative ERBB2-elicited immune response, we transplanted MT2 cells to MMTV-Erbb2 mice on the FVB/N background that had been tolerized to the Erbb2 oncogene 14 . The results were almost identical to those obtained in normal FVB/N mice (Fig. 1c) . Silencing of RANK expression ( Supplementary Fig. 1f ) reduced the pulmonary metastasis of MT2 cells (Fig. 1d) and blocked the response of MT2 cells to RANKL (Supplementary Fig. 2a ). Neither administration of RANKL nor silencing of RANK expression significantly influenced the primary tumorigenic growth of MT2 cells, which was identical in FVB/N mice and MMTV-Erbb2 mice on the FVB/N background ( Supplementary Fig. 2b, c) . Similar results were obtained by administration of a RANK-Fc fusion protein, which blocks RANK signalling 15 , to mice bearing MT2 mammary tumours. Whereas RANK-Fc marginally inhibited tumour growth at the primary site, it greatly reduced pulmonary metastasis ( Supplementary Fig. 3 ).
RANK engagement induced nuclear translocation and phosphorylation of IKK-a molecules that were not associated with IKK-b and IKK-c (also known as NEMO), the two other subunits of the IKK complex ( Supplementary Fig. 4a-c) . This finding indicates that free IKK-a or IKK-a that belongs to a complex of a different composition is targeted by RANK. Such RANK-induced IKK-a activation repressed expression of the metastasis inhibitor maspin (also known as SERPINB5) ( Supplementary Fig. 5a-c) . MT2 cells that overexpressed ectopic maspin (maspin-MT2 cells) showed marginally reduced tumorigenic growth but much less pulmonary metastasis (Supplementary Fig. 5d-g ). Treatment with exogenous RANKL stimulated the metastasis of enhanced green fluorescent protein (eGFP)-expressing MT2 cells but did not affect the growth of primary tumours from either maspin-MT2 or eGFP-expressing MT2 cells; moreover, it did not enhance the weak metastatic activity of maspin-MT2 cells (Supplementary Fig. 5h ). As expected 5 , the silencing of IKK-a expression in MT2 cells slowed tumorigenic growth ( Supplementary Fig. 6a, b) , blocked pulmonary metastasis, even in mice given exogenous RANKL ( Supplementary Fig. 6c ), and upregulated maspin expression (Supplementary Fig. 6d) .
Treatment of primary tumour cells or cells that had reduced Rank gene dosage with RANKL did not affect the formation of primary mammospheres ( Supplementary Fig. 7a, b) . Although RANKL was reported to stimulate metastasis by enhancing cancer cell motility 16 , no significant effect of RANKL on motility or invasiveness of MT2 cells was observed ( Supplementary Fig. 7c ). In vivo, treatment with RANKL led to fewer apoptotic cells in late-stage tumours ( Supplementary Fig. 7d ). Conversely, silencing of IKK-a expression increased the number of apoptotic cells in late-stage tumours by 2.2 fold, and this increase was not reversed by treatment with RANKL ( Supplementary Fig. 7e, f) . Preincubation of tail-vein-injected MT2 cells in RANKL and subsequent in vivo treatment with RANKL enhanced the extravasation of MT2 cells into the lungs in a RANK-dependent manner ( Supplementary Fig. 7g ). In vitro, RANKL strongly inhibited the apoptosis of suspended MT2 cells ( Supplementary Fig. 7h ). Hence, the pro-metastatic effect of RANKL and IKK-a may be due to the increased survival of circulating metastasis-initiating cells.
For Erbb2-induced mammary tumours, RANKL expression was detected in the surrounding stroma but not in the carcinoma portion ( Fig. 2a and Supplementary Fig. 8a , b) or in metastatic lung nodules, which were surrounded by a few CD5
1 lymphocytes ( Supplementary  Fig. 8a ). Activated lymphocytes produce RANKL during inflammation 17 and are present in breast tumours 18 . We therefore examined their role in tumour RANKL expression. The staining of sequential tumour sections showed an almost identical distribution of RANKL 1 cells and CD5 1 lymphocytes (Fig. 2a) . Correspondingly, tumours grown in recombination activating gene 1 (Rag1) 2/2 mice, which lack mature T and B cells ( Supplementary Fig. 9 ), contained less Rankl messenger RNA than did tumours in wild-type mice ( Fig. 2b ) and were devoid of RANKL 1 cells (Fig. 2a) . Decreased Rankl mRNA was also seen in tumours grown in Cd4 2/2 mice ( Fig. 2c) , which lack only CD4 1 T cells ( Supplementary Fig. 9 ). Tumours in Cd4 2/2 mice were almost completely devoid of RANKL 1 cells, although they contained a few CD5 1 cells (Fig. 2a ). To identify further the major RANKL-expressing cell type during metastatic spread, we grew MT2 cells in Rag1 2/2 mammary glands that had been reconstituted with splenic B cells, CD4
1 T cells or CD8
T cells from FVB/N mice. Reconstitution efficiency was confirmed by flow cytometry ( Supplementary Fig. 10 ). Only CD4 1 T cells substantially increased tumour Rankl mRNA above the low basal level in mock-reconstituted Rag1 2/2 mice ( Supplementary Fig. 11a ). We analysed B cells, CD4
1 T cells and CD8 1 T cells from spontaneous MMTV-Erbb2 tumours for Rankl mRNA and found this to be at the highest level in CD4 1 T cells ( Supplementary Fig. 11b ). Likewise, CD4
1 T cells from MT2 tumours contained much more Rankl mRNA than B cells from MT2 tumours ( Supplementary Fig. 11c ). Despite their lower contribution to Rankl mRNA, tumoral CD8
1 T cells were more numerous than CD4 1 T cells, and both T-cell subsets were far more abundant than tumoral B cells (Supplementary Fig.  12a ). The absence of lymphocytes in Rag1 2/2 mice did not affect the number of tumour-associated macrophages ( Supplementary Fig.  12b ), and no differences in stromal constituents were found between tumours grown in FVB/N mice and those in MMTV-Erbb2 mice on the FVB/N background ( Supplementary Fig. 2d, e) . 
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Among CD4
1 T-cell types, FOXP3 1 regulatory T (T reg ) cells showed the most similar distribution to RANKL 1 cells in mammary tumours (Fig. 2d) . Notably, T reg cells in breast tumours are associated with an invasive phenotype and poor prognosis 9, 10 . Most FOXP3 1 and RANKL 1 cells were in contact with stromal SMA 1 cells (Fig. 2d) . Congruently, CD4
1
CD25
1 tumoral T cells, which are FOXP3 enriched 19 , expressed fourfold more Rankl mRNA than CD4
1
CD25
2 T cells (Fig. 2e) . Furthermore, FOXP3 and RANKL were co-localized in tumours ( Supplementary Fig. 13a ). These results suggest that tumour-infiltrating CD4
1
FOXP3
1 T reg cells are the most critical cells for maintaining RANKL expression in the micro-environment of metastatic mammary tumours.
The proximity of RANKL 1 T cells to SMA 1 cells, which expressed fibroblast markers (Supplementary Fig. 14) , prompted us to examine whether SMA 1 cells express T-cell-attracting chemokines. CCchemokine ligand 5 (CCL5; also known as RANTES), a T-cell-attracting chemokine involved in breast cancer metastasis 20, 21 , was expressed by cancer-associated myofibroblasts (CAFs) but not by PCaM cells (Fig. 2f) . Expression of CC-chemokine receptor 1 (CCR1), one of the cognate receptors for CCL5 (ref. 22) , was increased in tumour CD4
1 T cells relative to splenic CD4 1 T cells ( Supplementary Fig. 13b, left) . Notably, tumoral CD4
1
CD25
1 T cells expressed more Ccr1 mRNA than their CD4
1
CD25
2 T-cell counterparts ( Supplementary Fig. 13b,  right) . Furthermore, tumoral FOXP3
1 T cells were in close proximity to CCL5
1 stromal cells (Fig. 2g) . Similarly, in in vitro experiments, CAFs attracted more CD4
1
CD25
1 T cells than CD4
1
CD25
2 T cells from spleens of tumour-bearing mice, although the latter were sixfold more abundant (Fig. 2h, left) . Recruitment was partly dependent on CCL5 (Fig. 2h, right) . Neutralization of CCL5 also inhibited the recruitment of tumoral CD25
1 T cells in vivo (Fig. 2i) . To examine the requirement for T cells for pulmonary metastasis, we transplanted freshly isolated PCaM cells to the mammary glands of Fig. 15a ), pulmonary metastasis was greatly diminished in Cd4 2/2 mice and Rag1 2/2 mice but unaltered in Cd8 2/2 mice compared with wild-type mice ( Fig. 3a and Supplementary Fig. 15b ). Erbb2 mRNA quantification confirmed a threefold decrease in pulmonary metastasis in Cd4 2/2 mice (Fig. 3b) . MT2-cell-inoculated Rag1 2/2 mice showed substantially reduced metastasis compared with MT2-cell-inoculated wild-type mice (Fig. 3c) , but this was restored by transplanting CD4
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1 T cells, which were much more effective at restoring metastasis than CD8
1 T cells or B cells (Fig. 3d) . Treatment with exogenous RANKL restored pulmonary metastasis in the absence of T cells (Fig. 3e) . CD4
1
CD25
1 T cells were far more effective at restoring pulmonary metastasis in MT2-cell-inoculated Rag1 2/2 mice than were CD4 1 CD25 -T cells (Fig. 3f) , and this effect was almost completely blocked by administering RANK-Fc (Fig. 3g) .
We examined whether RANKL stimulates the metastasis of human breast carcinoma cells. Of 19 carcinoma cell lines, the lines AU565, SK-BR-3, ZR-75-1 and SUM1315 expressed the most RANK protein or mRNA ( Fig. 4a and Supplementary Fig. 16a) . None of the cell lines expressed more Rankl mRNA than did untreated human mammary epithelial cells, which expressed RANKL only after treatment with progesterone ( Supplementary Fig. 16b ). ZR-75-1 and AU565 cells were inoculated into the number 2 mammary glands of nude mice (which lack mature T cells), and only ZR-75-1 cells formed slow growing primary tumours (data not shown), which gave rise to pulmonary metastases in 20% of mice, with an average multiplicity lower than 1 (Fig. 4b) .
Administration of human RANKL increased metastasis incidence and multiplicity (Fig. 4b) and decreased maspin mRNA expression by ZR-75-1 cells (Fig. 4c) . The carcinoma cell line T-47D, which is RANK 2 , did not respond to RANKL (Supplementary Fig. 17 ). In the stroma of human breast cancers, RANKL 1 and FOXP3 1 cells were present in close proximity to SMA 1 cells (Fig. 4d) . RANKL expression was higher in invasive ductal carcinomas than in ductal carcinomas in situ or lymph-node-positive tumours (Fig. 4e) .
Our results provide a new mechanistic explanation for the association of CD4
1 T-cell and T reg -cell markers with a more aggressive behaviour in advanced breast cancers 9, 10, 18, 23 , by demonstrating that tumour-infiltrating CD4
FOXP3
1 T reg cells are a major source of RANKL, which stimulates the metastatic progression of RANK-expressing breast/mammary carcinoma cells ( Supplementary  Fig. 18 ). These findings and the demonstration that the pro-metastatic function of T cells can be replaced by exogenous RANKL differ from those obtained using the MMTV-PyMT mouse model of mammary carcinogenesis, in which CD4
1 T helper 2 cells stimulate tumour progression through production of interleukin-4 and polarization of tumour-associated macrophages towards M2 macrophages 18 . Our mouse results correlate well with human breast cancer studies. In both cases, RANKL 1 and FOXP3 1 T reg cells are concentrated in the tumour stroma and do not come into contact with carcinoma cells. Furthermore, in both cases, the presence of tumoral T reg cells correlates with invasion, metastasis and poor prognosis 9, 10, 23, 24 . The recruitment of T reg cells to CAFs is partly dependent on CCL5, a chemokine whose presence is associated with higher grades of human breast cancer and metastasis 20, 21 . Our suggestion that CAFs and CCL5 act through T cells, LETTER RESEARCH in addition to having direct effects on carcinoma cells 20 , fits the observation that the depletion of CAFs from mammary tumours decreased T reg -cell infiltration and pulmonary metastasis 25 . We postulate that the potent pro-metastatic effect of tumour-infiltrating T reg cells can be dismantled by RANKL-RANK antagonists, which should leave the potential antitumorigenic activity of T helper 1 cells and CD8
1 T cells intact. Such inhibitors of RANK signalling need to be used together with the surgical resection of primary breast tumours and the administration of antitumour immunotherapy to prevent the recurrence of metastatic disease, but may be an ineffective treatment after metastasis recurs. RANKL has also been reported to act at an early stage of tumour development, at which it mediates the tumour-promoting effect of progestins 26, 27 . Thus, RANKL antagonists may also have a preventive ability. , Cd8 2/2 and Rag1 2/2 mice were maintained on the FVB/ N background. PCaM or MT2 single-cell suspensions were injected into the number 2 mammary gland. Tumour size was measured weekly with a caliper. At the study's end, mice were killed, and primary tumours and lungs were analysed. RESEARCH LETTER
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